Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
We now rank 3rd in pharmaceutical production by volume and 14th by value
Subscribe To Our Newsletter & Stay Updated
